{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:17:18Z","timestamp":1791404238531,"version":"4.3.3"},"reference-count":41,"publisher":"European Respiratory Society (ERS)","issue":"4","funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2015,5,28]]},"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:p>This randomised double-blind placebo-controlled parallel-group multicentre phase IIa study evaluated the effect of the CXCR2 antagonist AZD5069 on sputum neutrophil counts in adults with bronchiectasis.<\/jats:p><jats:p>Patients were randomised 1:1 to receive AZD5069 80\u2005mg or placebo orally twice daily for 28\u2005days. Assessments included blood cell counts, inflammatory markers in blood, morning spontaneous sputum, lung function, safety and tolerability and patients completed daily BronkoTest diary cards. The primary outcome measure was the change in absolute sputum neutrophil count.<\/jats:p><jats:p>Of 52 randomised patients, 45 completed treatment, 20 (76.9%) out of 26 receiving AZD5069 and 25 (96.2%) out of 26 receiving placebo. AZD5069 reduced the absolute neutrophil cell count in morning sputum by 69%<jats:italic>versus<\/jats:italic>placebo (p=0.004); percentage sputum neutrophil count was reduced by 36% (p=0.008). The number of infections\/exacerbations was similar with AZD5069 and placebo (nine<jats:italic>versus<\/jats:italic>eight), but these led to more study discontinuations with AZD5069 (four<jats:italic>versus<\/jats:italic>zero). Sputum interleukin (IL)-6 and growth-regulated oncogene (GRO)-\u03b1 and serum GRO-\u03b1, IL-1\u00df and IL-8 levels increased with AZD5069<jats:italic>versus<\/jats:italic>placebo (all p&lt;0.001), while serum high-sensitivity C-reactive protein levels did not change. AZD5069 was well tolerated.<\/jats:p><jats:p>AZD5069 markedly reduced absolute sputum neutrophil counts in bronchiectasis patients, although this was not associated with improvements in clinical outcomes in this exploratory study.<\/jats:p>","DOI":"10.1183\/13993003.00148-2015","type":"journal-article","created":{"date-parts":[[2015,9,8]],"date-time":"2015-09-08T18:38:35Z","timestamp":1441737515000},"page":"1021-1032","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":109,"title":["A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis"],"prefix":"10.1183","volume":"46","author":[{"given":"Anthony","family":"De Soyza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Stuart","family":"Elborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Wray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareta","family":"Puu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2015,9,4]]},"reference":[{"key":"2024102023403103000_46.4.1021.1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thx.2010.136119","article-title":"British Thoracic Society guideline for non-CF bronchiectasis","volume":"65: Suppl. 1","author":"Pasteur","year":"2010","journal-title":"Thorax"},{"key":"2024102023403103000_46.4.1021.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201210-1937OC"},{"key":"2024102023403103000_46.4.1021.3","doi-asserted-by":"publisher","DOI":"10.4104\/pcrj.2011.00007"},{"key":"2024102023403103000_46.4.1021.4","unstructured":"European Respiratory Society. European Lung White Book: Editors\u2019 Introduction. www.erswhitebook.org\/chapters\/editors-introduction\/ Date last accessed: April 9, 2015."},{"key":"2024102023403103000_46.4.1021.5","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Global Initiative For Asthma, 2015."},{"key":"2024102023403103000_46.4.1021.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2011.02.002"},{"key":"2024102023403103000_46.4.1021.7","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.119411"},{"key":"2024102023403103000_46.4.1021.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15650-X"},{"key":"2024102023403103000_46.4.1021.9","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00186109"},{"key":"2024102023403103000_46.4.1021.10","first-page":"CD000996","article-title":"Inhaled steroids for bronchiectasis","volume":"1","author":"Kapur","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102023403103000_46.4.1021.11","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.043182"},{"key":"2024102023403103000_46.4.1021.12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200511-1808OC"},{"key":"2024102023403103000_46.4.1021.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2780"},{"key":"2024102023403103000_46.4.1021.14","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202893"},{"key":"2024102023403103000_46.4.1021.15","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.119040"},{"key":"2024102023403103000_46.4.1021.16","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1003495"},{"key":"2024102023403103000_46.4.1021.17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00048509"},{"key":"2024102023403103000_46.4.1021.18","first-page":"209s","article-title":"Inhibition of LPS-induced neutrophilic inflammation in healthy volunteers","volume":"30: Suppl. 1","author":"O'Connor","year":"2007","journal-title":"Eur Respir J"},{"key":"2024102023403103000_46.4.1021.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2011.03921.x"},{"key":"2024102023403103000_46.4.1021.20","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-14-137"},{"key":"2024102023403103000_46.4.1021.21","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.2.9607083"},{"key":"2024102023403103000_46.4.1021.22","unstructured":"Jones PW . St George's Respiratory Questionnaire Manual. London, Division of Cardiac and Vascular Science, St George's, University of London, 2009."},{"key":"2024102023403103000_46.4.1021.23","first-page":"3984","article-title":"Safety and tolerability of single doses of AZD5069 in healthy volunteers","volume":"38: Suppl. 55","author":"Wray","year":"2011","journal-title":"Eur Respir J"},{"key":"2024102023403103000_46.4.1021.24","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-106-2-196"},{"key":"2024102023403103000_46.4.1021.25","unstructured":"Lichtman MA , Beutler E , Kaushansky K . Williams Hematology. 7th Edn. New York, McGraw-Hill Companies, 2006."},{"key":"2024102023403103000_46.4.1021.26","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00194611"},{"key":"2024102023403103000_46.4.1021.27","first-page":"78","article-title":"Safety and tolerability of AZD5069 in healthy smokers following multiple ascending doses","volume":"14","author":"Wray","year":"2012","journal-title":"Int J Immunorehab"},{"key":"2024102023403103000_46.4.1021.28","first-page":"3083","article-title":"The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD","volume":"40: Suppl. 56","author":"Kirsten","year":"2012","journal-title":"Eur Respir J"},{"key":"2024102023403103000_46.4.1021.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.10.007"},{"key":"2024102023403103000_46.4.1021.30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2290"},{"key":"2024102023403103000_46.4.1021.31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1937"},{"key":"2024102023403103000_46.4.1021.32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4415"},{"key":"2024102023403103000_46.4.1021.33","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood.V86.7.2559.2559","article-title":"Chemokine regulation of human megakaryocytopoiesis","volume":"86","author":"Gewirtz","year":"1995","journal-title":"Blood"},{"key":"2024102023403103000_46.4.1021.34","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.01.00057901"},{"key":"2024102023403103000_46.4.1021.35","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00144307"},{"key":"2024102023403103000_46.4.1021.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2004.01884.x"},{"key":"2024102023403103000_46.4.1021.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.12.009"},{"key":"2024102023403103000_46.4.1021.38","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00071312"},{"key":"2024102023403103000_46.4.1021.39","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00016908"},{"key":"2024102023403103000_46.4.1021.40","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.3.926"},{"key":"2024102023403103000_46.4.1021.41","first-page":"A6071","article-title":"CXCR2 Antagonist Mk-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease","volume":"187","author":"Rennard","year":"2013","journal-title":"Am J Respir Crit Care Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00148-2015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:59:06Z","timestamp":1740380346000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00148-2015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,4]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,9,30]]},"published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1183\/13993003.00148-2015"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00148-2015","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,4]]}}}